HK1123740A1 - Metalloproteinase binding proteins - Google Patents
Metalloproteinase binding proteinsInfo
- Publication number
- HK1123740A1 HK1123740A1 HK09103460.6A HK09103460A HK1123740A1 HK 1123740 A1 HK1123740 A1 HK 1123740A1 HK 09103460 A HK09103460 A HK 09103460A HK 1123740 A1 HK1123740 A1 HK 1123740A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- binding proteins
- metalloproteinase binding
- metalloproteinase
- proteins
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75537605P | 2005-12-30 | 2005-12-30 | |
US80556706P | 2006-06-22 | 2006-06-22 | |
US87056606P | 2006-12-18 | 2006-12-18 | |
PCT/US2006/049566 WO2007079218A2 (fr) | 2005-12-30 | 2006-12-29 | Proteines de liaison a la metalloproteinase |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1123740A1 true HK1123740A1 (en) | 2009-06-26 |
Family
ID=38228870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103460.6A HK1123740A1 (en) | 2005-12-30 | 2009-04-15 | Metalloproteinase binding proteins |
Country Status (8)
Country | Link |
---|---|
US (3) | US7745587B2 (fr) |
EP (1) | EP1981538B1 (fr) |
JP (2) | JP2009522302A (fr) |
AU (1) | AU2006332713B2 (fr) |
CA (1) | CA2635588C (fr) |
ES (1) | ES2524015T3 (fr) |
HK (1) | HK1123740A1 (fr) |
WO (1) | WO2007079218A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1539235A2 (fr) * | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Anticorps qui se lient specifiquement a reg iv |
PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
WO2007079218A2 (fr) * | 2005-12-30 | 2007-07-12 | Dyax Corp. | Proteines de liaison a la metalloproteinase |
US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
JP2011506614A (ja) * | 2007-12-17 | 2011-03-03 | ダイアックス コーポレーション | Mmp−14結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法 |
WO2009079581A1 (fr) * | 2007-12-17 | 2009-06-25 | Dyax Corp. | Evaluation de l'expression de mmp dans la stratification des patients et autres procédés thérapeutiques, diagnostiques et pronostiques du cancer |
WO2009097397A2 (fr) * | 2008-01-30 | 2009-08-06 | Dyax Corp. | Protéines de liaison à la métalloprotéinase |
WO2009132251A2 (fr) * | 2008-04-25 | 2009-10-29 | Dyax Corp. | Procédés et compositions comprenant des anticorps anti-idiotypiques à des anticorps anti-mmp-14 |
US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
WO2010048432A1 (fr) * | 2008-10-22 | 2010-04-29 | Dyax Corp. | Polythérapie comportant des protéines de liaison de protéase pour des troubles inflammatoires |
CN101732348B (zh) * | 2008-11-11 | 2015-01-14 | 威世药业(如皋)有限公司 | 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途 |
EP2697649A4 (fr) * | 2011-04-15 | 2015-04-22 | Nuclea Biotechnologies Inc | Profil d'expression génique de réponse thérapeutique à des inhibiteurs du vegf |
WO2013059439A2 (fr) * | 2011-10-21 | 2013-04-25 | Dyax Corp. | Polythérapie comprenant une protéine de liaison à la mmp-14 |
WO2013070468A1 (fr) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Anticorps spécifique de glypican-3 et ses utilisations |
EP2852383A4 (fr) * | 2012-05-21 | 2016-03-16 | Dcb Usa Llc | Procédés de dépistage des drogues au moyen du modèle du fouille-roche et composés ainsi dépistés |
CN102718840B (zh) * | 2012-08-06 | 2014-05-14 | 中山大学 | 一种人mmp-14抗原、相应单克隆抗体及其应用 |
JP6449772B2 (ja) | 2012-10-05 | 2019-01-09 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | ヒト抗vegfr2/kdr抗体 |
US20140235552A1 (en) * | 2013-02-15 | 2014-08-21 | Claresa Levetan | Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent |
WO2015100409A2 (fr) | 2013-12-26 | 2015-07-02 | Tufts University | Procédés, compositions et kits de traitement d'un sujet à l'aide d'une protéine de liaison neutralisante recombinante |
WO2018067198A1 (fr) | 2016-10-03 | 2018-04-12 | The Regents Of The University Of California | Anticorps inhibiteurs et leurs procédés d'utilisation |
US11332546B2 (en) | 2019-05-21 | 2022-05-17 | The Regents Of The University Of California | Protease inhibitory antibodies and methods of use thereof |
CN118085092A (zh) * | 2022-06-30 | 2024-05-28 | 深圳市乐土生物医药有限公司 | 分离的抗人Claudin18.2抗体及其应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB685557A (en) | 1950-02-25 | 1953-01-07 | Hans Spengler | Improved device for transporting warp beams of looms |
GB750672A (en) | 1953-06-16 | 1956-06-20 | Babcock & Wilcox Ltd | Improvements in or relating to tubular y-pieces |
JPS6048486B2 (ja) | 1976-01-01 | 1985-10-28 | 木場 常義 | 抗リウマチ剤 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP2694604B2 (ja) | 1993-11-30 | 1997-12-24 | 富士薬品工業株式会社 | 新規なメタロプロテアーゼおよびそれをコードするdna |
JPH07303482A (ja) * | 1993-11-30 | 1995-11-21 | Fuji Yakuhin Kogyo Kk | 新規なメタロプロテアーゼおよびそれをコードするdna |
US6825024B1 (en) * | 1993-11-30 | 2004-11-30 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Metalloproteinase and encoding DNA therefor |
JP4137997B2 (ja) | 1994-01-11 | 2008-08-20 | ダイアックス コープ. | クニッツドメインから誘導されたヒトプラスミンの阻害剤 |
WO1995025171A2 (fr) * | 1994-03-17 | 1995-09-21 | Max-Delbrück-Centrum für Molekulare Medizin | Sequences d'adn pour metalloproteases matricielles, leur production et leur utilisation |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5854015A (en) | 1995-10-31 | 1998-12-29 | Applied Food Biotechnology, Inc. | Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion |
GB9615976D0 (en) | 1996-07-30 | 1996-09-11 | Center For Clinical & Basic Re | The use of proteinase inhibitors for the prevention or reduction of bone resorption |
EP2314625B1 (fr) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Mammifères transgèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus |
US6087473A (en) | 1999-05-26 | 2000-07-11 | Zymogenetics, Inc. | Kunitz domain polypeptide and materials and methods for making it |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6984619B1 (en) | 1999-03-19 | 2006-01-10 | Arch Development Corporation | Method for protection against tumor metastasis formation |
US6339348B1 (en) * | 2000-09-12 | 2002-01-15 | Semiconductor Components Industries Llc | Programmable non-overlap time output driver |
EP1336851A4 (fr) * | 2000-11-20 | 2004-08-18 | Daiichi Fine Chem Co Ltd | Immunoessai pour metalloprotease a matrice liee a la membrane |
US20030181531A1 (en) | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
US20040192914A1 (en) | 2001-10-12 | 2004-09-30 | Kallander Lara S | Compounds and methods |
JP4511108B2 (ja) | 2002-05-31 | 2010-07-28 | オンコリクス インコーポレイテッド | ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質 |
US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
WO2004050683A2 (fr) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation |
US20040157278A1 (en) | 2002-12-13 | 2004-08-12 | Bayer Corporation | Detection methods using TIMP 1 |
ES2369498T3 (es) | 2003-04-04 | 2011-12-01 | Yeda Research And Development Co., Ltd. | Anticuerpos para inhibir la actividad de mmp-2 y mmp-9. |
CA2528001A1 (fr) | 2003-04-04 | 2004-10-21 | The University Of Tokyo | Structure de membrane lipidique comportant un anticorps monoclonal anti-mt-mmp |
US7485297B2 (en) | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
JP2007509610A (ja) | 2003-10-09 | 2007-04-19 | シーマインズ インコーポレイテッド | 皮膚癌を検出するための非侵襲性システム |
WO2005051299A2 (fr) | 2003-11-19 | 2005-06-09 | Dyax Corp. | Proteines de liaison aux metalloproteinases |
US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
WO2005110399A2 (fr) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Groupes de liaison au zinc pour inhibiteurs de metalloproteines |
AU2005272848A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
WO2006029385A2 (fr) * | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Antifoliques metaboliquement inertes utiles dans le traitement des maladies liees a la proliferation cellulaire anormale et a une inflammation |
AU2005316844A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
US7252536B2 (en) * | 2005-11-22 | 2007-08-07 | The Boeing Company | Self-aligning vibration resistant coupling apparatus |
WO2007079218A2 (fr) | 2005-12-30 | 2007-07-12 | Dyax Corp. | Proteines de liaison a la metalloproteinase |
JP5337493B2 (ja) | 2006-03-16 | 2013-11-06 | ダイアックス コーポレーション | セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法 |
US20080076120A1 (en) | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
WO2009079581A1 (fr) | 2007-12-17 | 2009-06-25 | Dyax Corp. | Evaluation de l'expression de mmp dans la stratification des patients et autres procédés thérapeutiques, diagnostiques et pronostiques du cancer |
JP2011506614A (ja) | 2007-12-17 | 2011-03-03 | ダイアックス コーポレーション | Mmp−14結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法 |
CA2717576A1 (fr) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Proteines de liaison a la metalloproteinase 9 |
WO2009111508A2 (fr) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2 |
US8012577B2 (en) | 2009-07-02 | 2011-09-06 | E.I. Du Pont De Nemours And Company | Composite article made by a process |
WO2011028883A2 (fr) | 2009-09-03 | 2011-03-10 | Dyax Corp. | Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2 |
-
2006
- 2006-12-29 WO PCT/US2006/049566 patent/WO2007079218A2/fr active Application Filing
- 2006-12-29 ES ES06848335.3T patent/ES2524015T3/es active Active
- 2006-12-29 JP JP2008548766A patent/JP2009522302A/ja not_active Withdrawn
- 2006-12-29 AU AU2006332713A patent/AU2006332713B2/en active Active
- 2006-12-29 EP EP06848335.3A patent/EP1981538B1/fr active Active
- 2006-12-29 US US11/648,423 patent/US7745587B2/en active Active
- 2006-12-29 CA CA2635588A patent/CA2635588C/fr active Active
-
2009
- 2009-04-15 HK HK09103460.6A patent/HK1123740A1/xx unknown
-
2010
- 2010-05-07 US US12/776,195 patent/US8106168B2/en active Active
-
2011
- 2011-12-22 US US13/335,185 patent/US9051377B2/en active Active
-
2013
- 2013-06-21 JP JP2013130580A patent/JP5898649B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US8106168B2 (en) | 2012-01-31 |
US7745587B2 (en) | 2010-06-29 |
EP1981538A4 (fr) | 2010-05-05 |
ES2524015T3 (es) | 2014-12-03 |
JP2013189473A (ja) | 2013-09-26 |
WO2007079218A2 (fr) | 2007-07-12 |
CA2635588A1 (fr) | 2007-07-12 |
US20070217997A1 (en) | 2007-09-20 |
AU2006332713A1 (en) | 2007-07-12 |
AU2006332713B2 (en) | 2013-01-17 |
EP1981538B1 (fr) | 2014-09-17 |
WO2007079218A3 (fr) | 2008-07-10 |
JP5898649B2 (ja) | 2016-04-06 |
JP2009522302A (ja) | 2009-06-11 |
US20120107231A1 (en) | 2012-05-03 |
CA2635588C (fr) | 2015-11-10 |
US20100266490A1 (en) | 2010-10-21 |
EP1981538A2 (fr) | 2008-10-22 |
US9051377B2 (en) | 2015-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2020009I2 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
EP1981538A4 (fr) | Proteines de liaison a la metalloproteinase | |
EP2262530A4 (fr) | Protéines de liaison à métalloprotéinase 12 | |
EP2262529A4 (fr) | Protéines de liaison à la métalloprotéinase 9 | |
GB0521991D0 (en) | Siglec-9 binding agents | |
IL188345A (en) | A binding protein specific to cd37 | |
GB0504767D0 (en) | Lipocalin protein | |
IL188671A0 (en) | Il-6 binding proteins | |
GB0514482D0 (en) | Protein | |
GB0520523D0 (en) | Object binding | |
GB0423974D0 (en) | Proteins | |
GB0511861D0 (en) | Proteins | |
FI20050547A0 (fi) | Side | |
GB0511799D0 (en) | Protein binding ligands | |
GB0522113D0 (en) | vWFA-domain containing proteins | |
GB0514788D0 (en) | Proteins | |
GB0513505D0 (en) | Proteins | |
GB0514481D0 (en) | Proteins | |
GB0504766D0 (en) | Metalloprotease protein | |
GB0515436D0 (en) | Protein | |
GB0508160D0 (en) | Protein | |
GB0513561D0 (en) | Protein | |
GB0515443D0 (en) | Protein | |
GB0514717D0 (en) | Protein | |
GB0513690D0 (en) | Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: CORRECTION OF THE NAME OF APPLICANT/PROPRIETOR FROM DYAX CORPORATION TO DYAX CORP |